ea0098c38 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023
Gupta Garima
, Yadav Rina
, Yan Donglin
, Anthony Lowell
, Ramirez Robert
, Chauhan Aman
Background: Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE (LUTATHERA) is an effective treatment option for somatostatin receptor (SSTR) positive metastatic gastroenteropancreatic neuroendocrine tumors (NETs) and has also demonstrated antitumor activity in SSTR positive NETs from other primary sites. While the median progression free survival (mPFS) is around 29 months, there is a subset of patients who are refractory to PRRT and demonstrate progressio...